• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Stocks

Uncharted Waters

This is an odd market right now.
By JAMES "REV SHARK" DEPORRE
Jan 06, 2015 | 04:40 PM EST
Stocks quotes in this article: FGEN, BLUE, KITE, OVAS, XNPT, AGEN, EYES, JUNO, BABA, TWTR, TSLA

The market is now 0 and 3 for 2015 and is on a five-day losing streak. Things were looking particularly poor at mid-day, which set us up for a little afternoon bounce, but we fizzled again into the close and were solidly red.

Breadth finished off its worst levels, but still quite poor with 1,650 gainers to 4,200 decliners. The most significant sector action was in biotechnology, which reversed hard after a strong start. Some of the high-flying biotech names like bluebird bio (BLUE), Kite Pharma (KITE) and Juno Therapeutics (JUNO) were chased by the momentum slowed down.

It's interesting to note that some of the lagging big-cap names such as Alibaba (BABA), Twitter (TWTR), and Tesla Motors (TSLA) managed positive action, but overall the big-cap momentum screens were a sea of red. Unlike yesterday, there weren't any easy places to hide. Without biotechnology, there simply isn't any leadership in this market now.

Of course, the main focus of many market players now is to try to figure out when we bottom. They feel lost and are uncertain about what to do, so they start focusing on a potential bounce. It is understandable, but it is a good way to suffer additional losses, if this downtrend gains momentum. Don't be too quick to conclude that the worst is over.

One thing to keep in mind as you contemplate this action is that every selloff we had in 2014 had at least one failed bounce before a big V-shaped bounce kicked in. If you were too quick to anticipate the inevitable run back up to new highs, you suffered some pains.

This is an odd market right now, with oil prices still falling, and bonds hitting levels few had anticipated, in the face of a more hawkish Fed. Basically, the worldwide economy stinks, and endless cheap cash isn't doing the same job it had done in the past.

Have a good evening. I'll see you tomorrow. 


JAN 06, 2015 | 1:53 PM EST

No Signs of Bottoming Action

  • Be patient and wait for the best entry points to develop.

I expressed my concern this morning about how biotechnology was the one safe haven in this market. Unfortunately, everyone seems to have realized that as well, which was the kiss of death. Biotechnology has rolled over hard and that is helping the market downtrend to gain traction.

While the senior indices are not down as much as yesterday, the underlying action feels much worse. We have traded straight down with just one minor attempted bounce. Breadth is extremely poor on the Nasdaq, with just 480 gainers to 2,220 losers. It is small-cap and momentum names that are leading to the downside, which gives the action a much more negative feel.

While the market is becoming oversold, so far there are no signs of bottoming action. There are still a few biotechs holding up, but there really is no place to hide today. If you are holding inventory, you have losses.

In this sort of action my strategy is to simply stay out of the way and ignore the folks who always try to push you to hurry up and buy. While we may see some sort of bounce soon, the chances that it will fail are high. This action is giving us some great potential opportunities down the road, but we'll need to be patient and wait for the best entry points to develop.


Jan. 06, 2015 | 10:50 AM EST

All About Biotech

  • With so many eyeballs on the sector, you have to be a bit nervous.

The dip buyers were ready to go to work but early weakness was needed to draw them in. Instead markets opened flat and had a dismal bounce attempt and now have rolled over on weaker-than-expected factory order and ISM Services numbers. That woke the dip buyers up, who now have the indices at a day's high, but there isn't much momentum, especially in the Nasdaq.

There's still strong action in the biotechnology group, but with so many eyeballs on the sector you have to be a little nervous. We have pure momentum in FibroGen (FGEN), Bluebird Bio (BLUE), Kite Pharma (KITE) and OvaScience (OVAS). Traders are shaking the bushes looking for the next mover in the group and their standards aren't very high.

Biotechnology is the only good momentum group out there, and that makes it very dangerous when there is so much focus on it. It's not as if this group hasn't already had a good run. I'm not calling a top but I'm going to be ready for a quick exit should the group start to reverse. Already I see OVAS, my stock of the week, reversing from early highs.

I like a few small-cap biotech setups, such as Xenoport (XNPT) and Agenus (AGEN), but they need more volume to pop. I also bottom-fished Second Sight Medical (EYES), but don't have much else new on the screens.

Unfortunately, without biotechnology there is little else of interest. Bottom-fishers trying to figure out oil and commodities, but technology is very mixed and there really is no leadership.

Markets are oversold enough for some sort of bounce but the potential of a failed bounce before a V-shaped recovery is very high. Stay selective and make sure you keep stops tight.


Jan. 06, 2015 | 7:52 AM EST

A Seasonal First

  • The current correction is a bit different.

I am incredibly bad at predicting the future; I am only smart enough to observe the present and listen to my intuition about tendencies.

--Rem Kookhaas

In 2014 the market underwent five fairly mild corrections. The worst one came in September and October, when the DJIA fell nearly 1500 points or 8.4%. In each case we had a failed bounce or two before we made a good low, but that was then followed by a straight up, V-shaped bounce back to highs.

The current corrective action is a bit different. First and foremost, it is occurring at a very odd time of the year, seasonally. This is the first time ever we have been down the last two days of the old year and the first two days of the New Year.

Action this time of the year is always driven by subjective considerations, like taxes and portfolio balancing rather than macro considerations, but this time the collapse in oil coincided with the market pressure. An additional factor has been that computer-driven trading programs took greater advantage of the thin trading and jerked us around more than usual.

Each of our prior corrections had been led by collapses in momentum and small-cap stocks. This correction has been driven more by falling oil and commodity prices. We also saw selling of some of the big 2014 winners over the last couple days to drive more selling pressure.

A couple positive notes are that there continue to be some positive pockets of action. Most notable, biotechnology has hardly flinched as this selling has played out, and there are a few safe havens in network security and chip names.

In the past it has always been dovish action by the Fed that has put support under this market. Market players have always felt secure that endless QE would prevent any long lasting correction. While the Fed is slightly more hawkish, we now have the potential of bond buying programs in both Europe and China. In addition, bond king Bill Gross has been predicting that the Fed may not even raise interest rates this year.

Long-term interest rates are near record lows, and with falling gasoline prices there is more cheap cash than ever sloshing around. While the weak economies in Europe and China are troubling, we should be very aware that the market is not correlated to the economy. If the market had reflected actual economic growth the last few years, we sure wouldn't be looking at all-time highs.

Should we be looking for another V-shaped bounce once this current corrective action plays out? Many market players thought it was unlikely we would see them continue in 2014, but we ended up with even bigger and more consistent V-bounces.

Given traders' penchant for embracing patterns, it is very likely that they will help to continue the inclination toward V-shaped bounces. Tendencies like this are self-fulfilling, since there is nothing worse than missing out when a pattern is so obvious.

I'm not predicting that the current correction has played out. I believe it is likely we have some sort of failed bounce try first, but action early in the year tends to be very random and we have earnings season quickly approaching as well.

At this juncture, the important thing is that we respect the fact of poor price action and make sure we don't allow losses to build. It is particularly important to be disciplined with money management in a market like this. You will very likely make some poor sales, but it is far more important to play defense than to force offense.

Although overseas markets were weak overnight and oil made a new low, we have a positive open on the way. Many traders were hoping for a gap down open they could buy, but the market never likes to make it too easy. 

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Rev Shark was long OVAS, BLUE, KITE, XNPT, AGEN and EYES, although positions may change at any time.

TAGS: Investing | U.S. Equity | Stocks

More from Stocks

As We Come Back From July 4, Market Fights a Hangover

James "Rev Shark" DePorre
Jul 5, 2022 4:22 PM EDT

After a rough start, we saw strength in some sectors that had taken it on the chin.

What's the Next Move for Crude Oil?

Bruce Kamich
Jul 5, 2022 3:30 PM EDT

A temporary break in oil prices, along with lower interest rates, could be a near-term positive for equity prices.

Can Nvidia Rally and Help the Tech Sector Recover?

Bruce Kamich
Jul 5, 2022 3:00 PM EDT

Why Tuesday could mark the start of a turnaround.

Tesla's Charts Are Resisting a Downside Break

Bruce Kamich
Jul 5, 2022 1:54 PM EDT

Here's what aggressive traders could do.

We Can't Predict the Rest of 2022, but We Must Have a Game Plan

Brad Ginesin
Jul 5, 2022 1:30 PM EDT

Many are forecasting bad times ahead, but are they going to extremes? Here's my strategy for the the second half of the year.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 12:01 PM EDT PAUL PRICE

    A Recent Director Buy in Children's Place (PLCE)

    Four of the most recent insider trades in Children...
  • 07:34 AM EDT PAUL PRICE

    A $525,000 Vote of Confidence on Macerich (MAC)

  • 09:49 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Stop Wishing, Hoping, and Praying and Take Control...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login